5q Syndrome
5q Syndrome 5q Syndrome is a distinct subtype of myelodysplastic syndrome (MDS) characterized by a specific deletion on chromosome 5, leading to impaired blood cell production. Understanding its causes, symptoms, and treatment options is essential for patients and healthcare providers managing this condition.
Key Takeaways
- 5q Syndrome is caused by a deletion of the long arm of chromosome 5, impairing normal bone marrow function.
- It predominantly affects older women and is classified as a low-risk form of MDS.
- Common symptoms include severe anemia, fatigue, and abnormal platelet counts.
- Lenalidomide is the primary FDA-approved treatment and achieves high rates of transfusion independence.
- Prognosis is generally more favorable than other MDS subtypes, though lifelong monitoring is required.
Causes, Diagnosis, and Symptoms of 5q Syndrome
Del 5q syndrome refers to a clonal bone marrow disorder caused by an isolated deletion of the long arm (q arm) of chromosome 5, specifically at band 5q31–5q33. This chromosomal loss disrupts genes responsible for regulating red blood cell maturation and platelet production. The exact trigger for this deletion is not fully understood, but it is considered an acquired genetic event rather than an inherited condition. It accounts for approximately 10–15% of all MDS cases, according to published hematology literature, and occurs most frequently in older women over the age of 60.
Diagnosis of del 5q syndrome relies on bone marrow biopsy and cytogenetic analysis, which confirms the characteristic chromosomal deletion. A complete blood count (CBC) typically reveals macrocytic anemia with a normal or elevated platelet count — a hallmark feature that helps distinguish this subtype from other forms of MDS. Flow cytometry and molecular testing may also be performed to rule out additional chromosomal abnormalities, as the presence of more than one deletion can affect both classification and prognosis.
The most prominent symptoms include:
- Chronic fatigue and weakness due to severe anemia
- Pallor and shortness of breath, particularly with exertion
- Dependence on red blood cell transfusions
- Occasionally, an elevated platelet count (thrombocytosis)
Notably absent in many patients are the increased infection rates and bleeding complications commonly seen in other MDS subtypes, which reflects the relatively preserved function of white blood cells and platelets in isolated del 5q cases.
5q Syndrome Treatment Options and MDS Prognosis
Treatment for 5q syndrome symptoms and treatment strategies center on reducing transfusion burden and improving quality of life. Lenalidomide, an immunomodulatory agent, is the cornerstone of therapy and has received FDA approval specifically for transfusion-dependent anemia in patients with low- or intermediate-1–risk MDS associated with the del 5q deletion. Clinical studies have shown that lenalidomide achieves transfusion independence in approximately 67% of treated patients, representing a significant therapeutic advance over supportive care alone.
For patients ineligible for or unresponsive to lenalidomide, erythropoiesis-stimulating agents (ESAs) may offer symptomatic benefit. In younger patients or those who progress to higher-risk disease, allogeneic stem cell transplantation may be considered, though it carries substantial procedural risk and is reserved for carefully selected cases.
| Treatment Approach | Indication | Key Benefit |
|---|---|---|
| Lenalidomide | Low/intermediate-1 risk del 5q MDS | High rate of transfusion independence |
| Erythropoiesis-stimulating agents | Lenalidomide ineligibility | Reduces transfusion frequency |
| Stem cell transplantation | High-risk progression | Potential curative option |
Regarding 5q syndrome MDS prognosis and outlook, patients with isolated del 5q generally fare better than those with other MDS subtypes. Median overall survival often exceeds several years with appropriate management, and transformation to acute myeloid leukemia (AML) occurs in a minority of cases — estimated at roughly 10% over 10 years. However, prognosis worsens if additional chromosomal abnormalities are present or if the condition evolves to a higher-risk MDS category. Regular hematologic monitoring and timely adjustment of therapy remain central to maintaining favorable long-term outcomes.
